Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Repessé Y[au]:

Potent Thrombolytic Effect of <i>N</i>-Acetylcysteine on Arterial Thrombi. Martinez de Lizarrondo S et al. Circulation. (2017)

F376A/M388A-solulin, a new promising antifibrinolytic for severe haemophilia A. Parcq J et al. Haemophilia. (2017)

Haematological complications of cystinosis. Cornet E et al. Eur J Haematol. (2015)

Search results

Items: 37

1.

Multicentre evaluation of CK Prest® for assaying plasma levels of factor IX fused with albumin (Idelvion® ).

Pouplard C, Galinat H, Ternisien C, Blanc Jouvan F, De Maistre E, Duchemin J, Flaujac C, Hézard N, Grand F, Le Cam-Duchez V, Marlu R, Mourey G, Nedelec F, Pineau-Vincent F, Repesse Y, Stépanian A, Szymezak J, Voisin S, Voyer AL, Jeanpierre E, Lasne D; French Study Group on Laboratory Management of bleeding disorders (BIMHO group).

Haemophilia. 2019 Jul 11. doi: 10.1111/hae.13812. [Epub ahead of print] No abstract available.

PMID:
31294887
2.

Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A.

Bachelet D, Albert T, Mbogning C, Hässler S, Zhang Y, Schultze-Strasser S, Repessé Y, Rayes J, Pavlova A, Pezeshkpoor B, Liphardt K, Davidson JE, Hincelin-Méry A, Dönnes P, Lacroix-Desmazes S, Königs C, Oldenburg J, Broët P; ABIRISK consortium.

PLoS One. 2019 Jun 13;14(6):e0218258. doi: 10.1371/journal.pone.0218258. eCollection 2019.

3.

Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A.

Repessé Y, Costa C, Palla R, Moshai EF, Borel-Derlon A, D'Oiron R, Rothschild C, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Oldenburg J, Pavlova A, Rosendaal FR, Peyvandi F, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2019 Aug;104(8):e369-e372. doi: 10.3324/haematol.2018.212001. Epub 2019 Jan 31. No abstract available.

4.

Evaluation of the impact of S-adenosylmethionine-dependent methyltransferase inhibitor, 3-deazaneplanocin A, on tissue injury and cognitive function in mice.

Lhuissier E, Aury-Landas J, Bouet V, Bazille C, Repesse Y, Freret T, Boumédiene K, Baugé C.

Oncotarget. 2018 Apr 17;9(29):20698-20708. doi: 10.18632/oncotarget.25062. eCollection 2018 Apr 17.

5.

Point of Care Tests VerifyNow P2Y12 and INNOVANCE PFA P2Y Compared to Light Transmittance Aggregometry After Fibrinolysis.

Roule V, Ardouin P, Repessé Y, Le Querrec A, Blanchart K, Lemaitre A, Sabatier R, Borel-Derlon A, Beygui F.

Clin Appl Thromb Hemost. 2018 Oct;24(7):1109-1116. doi: 10.1177/1076029618772354. Epub 2018 May 2.

PMID:
29719963
6.

Potent Thrombolytic Effect of N-Acetylcysteine on Arterial Thrombi.

Martinez de Lizarrondo S, Gakuba C, Herbig BA, Repessé Y, Ali C, Denis CV, Lenting PJ, Touzé E, Diamond SL, Vivien D, Gauberti M.

Circulation. 2017 Aug 15;136(7):646-660. doi: 10.1161/CIRCULATIONAHA.117.027290. Epub 2017 May 9.

7.

F376A/M388A-solulin, a new promising antifibrinolytic for severe haemophilia A.

Parcq J, Petersen KU, Borel-Derlon A, Gautier P, Ebel M, Vivien D, Repessé Y.

Haemophilia. 2017 Mar;23(2):319-325. doi: 10.1111/hae.13126. Epub 2016 Dec 8.

PMID:
27928886
8.

Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia: A retrospective single-center study.

Vautier M, de Boysson H, Creveuil C, Repesse Y, Borel-Derlon A, Troussard X, Damaj GL, Bienvenu B, Gautier P, Aouba A.

Medicine (Baltimore). 2016 Nov;95(48):e5232.

9.

Impact of alcohol consumption on the outcome of ischemic stroke and thrombolysis: role of the hepatic clearance of tissue-type plasminogen activator.

Lemarchand E, Gauberti M, Martinez de Lizarrondo S, Villain H, Repessé Y, Montagne A, Vivien D, Ali C, Rubio M.

Stroke. 2015 Jun;46(6):1641-50. doi: 10.1161/STROKEAHA.114.007143. Epub 2015 Apr 28.

PMID:
25922513
10.

Endovascular abdominal aortic aneurysm repair in a mild haemophilia A patient: a case report.

Gautier P, Repesse Y, Joguet E, Troussard X, Borel-Derlon A, Berger L.

Haemophilia. 2015 May;21(3):e232-5. doi: 10.1111/hae.12640. Epub 2015 Feb 16. No abstract available.

PMID:
25684019
11.

Haematological complications of cystinosis.

Cornet E, Repesse Y.

Eur J Haematol. 2015 Feb;94(2):187. doi: 10.1111/ejh.12331. Epub 2014 Apr 9. No abstract available.

PMID:
24684142
12.

Octreotide for recurrent intestinal bleeding due to ventricular assist device.

Coutance G, Saplacan V, Belin A, Repessé Y, Buklas D, Massetti M.

Asian Cardiovasc Thorac Ann. 2014 Mar;22(3):350-2. doi: 10.1177/0218492312474902. Epub 2013 Aug 16.

PMID:
24585917
13.

GpIbα-VWF blockade restores vessel patency by dissolving platelet aggregates formed under very high shear rate in mice.

Le Behot A, Gauberti M, Martinez De Lizarrondo S, Montagne A, Lemarchand E, Repesse Y, Guillou S, Denis CV, Maubert E, Orset C, Vivien D.

Blood. 2014 May 22;123(21):3354-63. doi: 10.1182/blood-2013-12-543074. Epub 2014 Feb 19.

14.

Predictive immunogenicity of Refacto AF.

Delignat S, Repessé Y, Gilardin L, Dimitrov JD, Lone YC, Kaveri SV, Lacroix-Desmazes S.

Haemophilia. 2014 Jul;20(4):486-92. doi: 10.1111/hae.12348. Epub 2013 Dec 30.

PMID:
24372710
15.

In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene.

Pashov AD, Calvez T, Gilardin L, Maillère B, Repessé Y, Oldenburg J, Pavlova A, Kaveri SV, Lacroix-Desmazes S.

Haemophilia. 2014 Mar;20(2):176-84. doi: 10.1111/hae.12276. Epub 2013 Oct 14.

PMID:
24118514
16.

The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status.

Rayes J, Roumenina LT, Dimitrov JD, Repessé Y, Ing M, Christophe O, Jokiranta TS, Halbwachs-Mecarelli L, Borel-Derlon A, Kaveri SV, Frémeaux-Bacchi V, Lacroix-Desmazes S.

Blood. 2014 Jan 2;123(1):121-5. doi: 10.1182/blood-2013-04-495853. Epub 2013 Sep 6.

17.

Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter.

Repessé Y, Peyron I, Dimitrov JD, Dasgupta S, Moshai EF, Costa C, Borel-Derlon A, Guillet B, D'Oiron R, Aouba A, Rothschild C, Oldenburg J, Pavlova A, Kaveri SV, Lacroix-Desmazes S; ABIRISK consortium.

Haematologica. 2013 Oct;98(10):1650-5. doi: 10.3324/haematol.2013.084665. Epub 2013 May 28.

18.

Deferoxamine blocks death induced by glutathione depletion in PC 12 cells.

Chouraqui E, Leon A, Repesse Y, Prigent-Tessier A, Bouhallab S, Bougle D, Marie C, Duval D.

Neurotoxicology. 2013 Jul;37:221-30. doi: 10.1016/j.neuro.2013.04.013. Epub 2013 May 13.

PMID:
23680049
19.

Hydrolysis of factor VIII mediated by catalytic antibodies occurs in haemophilia A patients with or without factor VIII inhibitors.

Grosbois SS, Brionne MF, de Longcamp AL, Gautier P, V Kaveri S, Borel-Derlon A, Repessé Y.

Haemophilia. 2013 Mar;19(2):322-9. doi: 10.1111/hae.12067. Epub 2012 Dec 6.

PMID:
23216758
20.

Thermodynamic analysis of the interaction of factor VIII with von Willebrand factor.

Dimitrov JD, Christophe OD, Kang J, Repessé Y, Delignat S, Kaveri SV, Lacroix-Desmazes S.

Biochemistry. 2012 May 22;51(20):4108-16. doi: 10.1021/bi300232d. Epub 2012 May 14.

PMID:
22559004
21.

Heme binds to factor VIII and inhibits its interaction with activated factor IX.

Repessé Y, Dimitrov JD, Peyron I, Farrokhi Moshai E, Kiger L, Dasgupta S, Delignat S, Marden MC, Kaveri SV, Lacroix-Desmazes S.

J Thromb Haemost. 2012 Jun;10(6):1062-71. doi: 10.1111/j.1538-7836.2012.04724.x.

22.

Mannose-sensitive receptors mediate the uptake of factor VIII therapeutics by human dendritic cells.

Repessé Y, Dasgupta S, Navarrete AM, Delignat S, Kaveri SV, Lacroix-Desmazes S.

J Allergy Clin Immunol. 2012 Apr;129(4):1172-3; author reply 1174-5. doi: 10.1016/j.jaci.2012.01.048. Epub 2012 Feb 14. No abstract available.

PMID:
22336079
23.

Acquired von Willebrand disease in Jarvik 2000 recipients: a single center experience.

Coutance G, Repessé Y, Belin A, Massetti M.

Int J Cardiol. 2012 Aug 9;159(1):57-8. doi: 10.1016/j.ijcard.2011.12.031. Epub 2012 Jan 10. No abstract available.

PMID:
22240762
24.

Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A.

Delignat S, Repessé Y, Navarrete AM, Meslier Y, Gupta N, Christophe OD, Kaveri SV, Lacroix-Desmazes S.

Haemophilia. 2012 Mar;18(2):248-54. doi: 10.1111/j.1365-2516.2011.02679.x. Epub 2011 Nov 2.

PMID:
22044692
25.

Proteolytic antibodies activate factor IX in patients with acquired hemophilia.

Wootla B, Christophe OD, Mahendra A, Dimitrov JD, Repessé Y, Ollivier V, Friboulet A, Borel-Derlon A, Levesque H, Borg JY, Andre S, Bayry J, Calvez T, Kaveri SV, Lacroix-Desmazes S.

Blood. 2011 Feb 17;117(7):2257-64. doi: 10.1182/blood-2010-07-296103. Epub 2010 Dec 3.

26.

Endocytic receptor for pro-coagulant factor VIII: relevance to inhibitor formation.

Navarrete AM, Dasgupta S, Teyssandier M, Repesse Y, Delignat S, André S, Bayry J, Kaveri SV, Lacroix-Desmazes S.

Thromb Haemost. 2010 Dec;104(6):1093-8. doi: 10.1160/TH10-05-0294. Epub 2010 Sep 30. Review.

PMID:
20886186
27.

Induction of heme oxygenase-1 in factor VIII-deficient mice reduces the immune response to therapeutic factor VIII.

Dimitrov JD, Dasgupta S, Navarrete AM, Delignat S, Repesse Y, Meslier Y, Planchais C, Teyssandier M, Motterlini R, Bayry J, Kaveri SV, Lacroix-Desmazes S.

Blood. 2010 Apr 1;115(13):2682-5. doi: 10.1182/blood-2009-04-216408. Epub 2009 Nov 4.

28.

Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody.

Dimitrov JD, Roumenina LT, Andre S, Repesse Y, Atanasov BP, Jacquemin M, Saint-Remy JM, Bayry J, Kaveri SV, Lacroix-Desmazes S.

Mol Immunol. 2009 Dec;47(2-3):290-7. doi: 10.1016/j.molimm.2009.09.021. Epub 2009 Oct 6.

PMID:
19811836
29.

Inhibitors of factor VIII in hemophilia.

Lacroix-Desmazes S, Dimitrov JD, Repesse Y.

N Engl J Med. 2009 Jul 16;361(3):308; author reply 310. doi: 10.1056/NEJMc091067. No abstract available.

PMID:
19605840
30.

A cellular viewpoint of anti-FVIII immune response in hemophilia A.

André S, Meslier Y, Dimitrov JD, Repessé Y, Kaveri SV, Lacroix-Desmazes S, Dasgupta S.

Clin Rev Allergy Immunol. 2009 Oct;37(2):105-13. doi: 10.1007/s12016-009-8117-2. Review.

PMID:
19165635
31.

The role of VWF in the immunogenicity of FVIII.

Lacroix-Desmazes S, Repessé Y, Kaveri SV, Dasgupta S.

Thromb Res. 2008;122 Suppl 2:S3-6. doi: 10.1016/S0049-3848(08)70002-1. Review.

PMID:
18549909
32.

Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.

Kaveri SV, Dasgupta S, Andre S, Navarrete AM, Repessé Y, Wootla B, Lacroix-Desmazes S.

Haemophilia. 2007 Dec;13 Suppl 5:61-4. doi: 10.1111/j.1365-2516.2007.01575.x. Review.

PMID:
18078399
33.

The electrophysiological effects of racemic ketamine and etomidate in an in vitro model of "border zone" between normal and ischemic/reperfused guinea pig myocardium.

Hanouz JL, Repesse Y, Zhu L, Lemoine S, Rouet R, Sallé L, Plaud B, Gérard JL.

Anesth Analg. 2008 Feb;106(2):365-70, table of contents. doi: 10.1213/ane.0b013e31816052b6.

PMID:
18227286
34.

Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation.

Dasgupta S, Navarrete AM, André S, Wootla B, Delignat S, Repessé Y, Bayry J, Nicoletti A, Saenko EL, d'Oiron R, Jacquemin M, Saint-Remy JM, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2008 Jan;93(1):83-9. doi: 10.3324/haematol.11535.

35.

Factor VIII (FVIII) gene mutations in 120 patients with hemophilia A: detection of 26 novel mutations and correlation with FVIII inhibitor development.

Repessé Y, Slaoui M, Ferrandiz D, Gautier P, Costa C, Costa JM, Lavergne JM, Borel-Derlon A.

J Thromb Haemost. 2007 Jul;5(7):1469-76. Epub 2007 Apr 18.

36.

VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.

Dasgupta S, Repessé Y, Bayry J, Navarrete AM, Wootla B, Delignat S, Irinopoulou T, Kamaté C, Saint-Remy JM, Jacquemin M, Lenting PJ, Borel-Derlon A, Kaveri SV, Lacroix-Desmazes S.

Blood. 2007 Jan 15;109(2):610-2. Epub 2006 Sep 19.

37.

Class III effects of dofetilide and arrhythmias are modulated by [K+]o in an in vitro model of simulated-ischemia and reperfusion in guinea-pig ventricular myocardium.

Ducroq J, Rouet R, Sallé L, Puddu PE, Repessé Y, Ghadanfar M, Ducouret P, Gérard JL.

Eur J Pharmacol. 2006 Feb 27;532(3):279-89. Epub 2006 Feb 14.

PMID:
16480976

Supplemental Content

Loading ...
Support Center